

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 JUL 12 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to BABS
NEWS 4 AUG 02 IFIPAT/IFIUDB/IFICDB reloaded with new search and display
fields
NEWS 5 AUG 02 CAPLUS and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 AUG 27 BIOCOMMERCE: Changes and enhancements to content coverage
NEWS 8 AUG 27 BIOTECHABS/BIOTECHDS: Two new display fields added for legal
status data from INPADOC
NEWS 9 SEP 01 INPADOC: New family current-awareness alert (SDI) available
NEWS 10 SEP 01 New pricing for the Save Answers for SciFinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HITSTR, available in WPIDS/WPINDEX/WPIX
NEWS 12 SEP 27 STANDARDS will no longer be available on STN
NEWS 13 SEP 27 SWETSCAN will no longer be available on STN
NEWS 14 OCT 28 KOREAPAT now available on STN

NEWS EXPRESS OCTOBER 29 CURRENT WINDOWS VERSION IS V7.01A, CURRENT
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:16:30 ON 09 NOV 2004

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

COMMAND INTERRUPTED

SEARCH ENDED BY USER

If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help
Desk by telephone or via SEND in the STNMAIL file.

=> s l4 and (release rate#)

L5 533 L4 AND (RELEASE RATE#)

=> s l5 and (adher? or stick or retain?)

L6 435 L5 AND (ADHER? OR STICK OR RETAIN?)

=> s l6 and catheter?

L7 243 L6 AND CATHETER?

=> s l7 and paclitaxel

L8 93 L7 AND PACLITAXEL

=> s l8 and fibrin

L9 36 L8 AND FIBRIN

=> d l9 1-36 ibib abs

L9 ANSWER 1 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:268745 USPATFULL

TITLE: Novel nanomagnetic particles

INVENTOR(S): Wang, Xingwu, Wellsville, NY, UNITED STATES

Greenwald, Howard J., Rochester, NY, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004210289	A1	20041021
APPLICATION INFO.:	US 2004-808618	A1	20040324 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-366082, filed on 13 Feb 2003, PENDING Continuation-in-part of Ser. No. US 2002-324773, filed on 18 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-90553, filed on 4 Mar 2002, PENDING Continuation-in-part of Ser. No. US 2002-229183, filed on 26 Aug 2002, PENDING Continuation-in-part of Ser. No. US 2002-242969, filed on 13 Sep 2002, PENDING Continuation-in-part of Ser. No. US 2002-260247, filed on 30 Sep 2002, GRANTED, Pat. No. US 6673999 Continuation-in-part of Ser. No. US 2002-273738, filed on 18 Oct 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671 Continuation-in-part of Ser. No. US 2002-313847, filed on 7 Dec 2002, PENDING Continuation-in-part of Ser. No. US 2002-303264, filed on 25 Nov 2002, GRANTED, Pat. No. US 6713671		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	HOWARD J. GREENWALD P.C., 349 W. COMMERCIAL STREET SUITE 2490, EAST ROCHESTER, NY, 14445-2408		
NUMBER OF CLAIMS:	98		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	51 Drawing Page(s)		
LINE COUNT:	11684		

AB A composition containing nanomagnetic particles. The, nanomagnetic particles have an average particle size of less than about 100 nanometers, a saturation magnetization of from about 2 to about 2,000 electromagnetic units per cubic centimeter, a phase transition temperature of from about 40 to about 200 degrees Celsius, and a squareness of from about 0.05 to about 1.0; the average coherence length

between adjacent nanomagnetic particles is less than about 100 nanometers; and the nanomagnetic particles are at least triatomic.

L9 ANSWER 2 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:260216 USPATFULL

TITLE: Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic **intimal hyperplasia**

INVENTOR(S): Helmus, Michael N., Worcester, MA, UNITED STATES
Cunanan, Crystal M., Mission Viejo, CA, UNITED STATES
Tremble, Patrice, Santa Rosa, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2004202711	A1	20041014
APPLICATION INFO.:	US 2004-816680	A1	20040402 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-771480, filed on 25 Jan 2001, GRANTED, Pat. No. US 6730313		

NUMBER	DATE
--------	------

PRIORITY INFORMATION:	US 2000-178087P	20000125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	EDWARDS LIFESCIENCES CORPORATION, ONE EDWARDS WAY, IRVINE, CA, 92614	
NUMBER OF CLAIMS:	47	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2003	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for treating injuries to one or more internal structures of a subject by administering a drug delivery vehicle to an external surface of the injured structure. The drug delivery vehicle substantially **adheres** to the site of administration and provides for the **release** of a bioactive agent that reduces or prevents further injury to the internal structure by disease processes, such as hyperplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 3 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:209805 USPATFULL

TITLE: Peptides which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, compositions and uses thereof

INVENTOR(S): Allan, Amy L., Encinitas, CA, UNITED STATES
Donate, Fernando, San Diego, CA, UNITED STATES
Hopkins, Stephanie A., Poway, CA, UNITED STATES
Gladstone, Patricia L., San Diego, CA, UNITED STATES
Mazar, Andrew, San Diego, CA, UNITED STATES
O'Hare, Sean M., San Diego, CA, UNITED STATES
Parry, Graham, San Diego, CA, UNITED STATES
Plunkett, Marian, San Diego, CA, UNITED STATES
Ternansky, Robert J., San Diego, CA, UNITED STATES
Yoon, Won Hyung, San Diego, CA, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION:	US 2004162239	A1	20040819
APPLICATION INFO.:	US 2003-723144	A1	20031125 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2002-429174P 20021125 (60)
 US 2003-475539P 20030602 (60)
 DOCUMENT TYPE: Utility
 FILE SEGMENT: APPLICATION
 LEGAL REPRESENTATIVE: COOLEY GODWARD, LLP, 3000 EL CAMINO REAL, 5 PALO ALTO
 SQUARE, PALO ALTO, CA, 94306
 NUMBER OF CLAIMS: 65
 EXEMPLARY CLAIM: 1
 NUMBER OF DRAWINGS: 5 Drawing Page(s)
 LINE COUNT: 3373
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates generally to peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, methods of making peptides, which inhibit angiogenesis, cell migration, cell invasion and cell proliferation, pharmaceutical compositions of these peptides and methods of using these peptides and pharmaceutical compositions of these peptides to treat diseases associated with aberrant vascularization.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 4 OF 36 USPATFULL on STN
 ACCESSION NUMBER: 2004:189778 USPATFULL
 TITLE: Perivascular wraps
 INVENTOR(S): Gravett, David M., Vancouver, CANADA
 Toleikis, Philip M., Vancouver, CANADA
 Guan, Dechi, Vancouver, CANADA
 Signore, Pierre E., Vancouver, CANADA
 Spencer, Thomas S., Bellingham, WA, UNITED STATES
 Hunter, William L., Vancouver, CANADA
 Wang, Kaiyue, Vancouver, CANADA
 PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA, V6A
 1B6 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004146546	A1	20040729
APPLICATION INFO.:	US 2003-673046	A1	20030926 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-414714P	20020926 (60)
	US 2002-414693P	20020927 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	231	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	10 Drawing Page(s)	
LINE COUNT:	2885	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions, devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic factors, inhibitors of smooth muscle cell growth or proliferation, non-steroidal anti-inflammatoary drugs, and other factors useful preventing and/or reducing a proliferative biological response that may obstruct or hinder the optimal functioning of the passageway or cavity.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 5 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:100811 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
Arsenault, A. Larry, Paris, CANADA
Burt, Helen M., Vancouver, CANADA
Jackson, John K., Vancouver, CANADA
Dordunoo, Stephen K., Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA
(non-U.S. corporation)
University of British Columbia, Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004076672	A1	20040422
APPLICATION INFO.:	US 2003-389262	A1	20030313 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-925220, filed on 8 Aug 2001, GRANTED, Pat. No. US 6544544 Continuation of Ser. No. US 1999-294458, filed on 19 Apr 1999, GRANTED, Pat. No. US 6506411 Continuation of Ser. No. US 1995-480260, filed on 7 Jun 1995, ABANDONED Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	76 Drawing Page(s)	
LINE COUNT:	5237	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 6 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:82360 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
Arsenault, A. Larry, Paris, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004062810	A1	20040401
APPLICATION INFO.:	US 2003-390534	A1	20030314 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-925220, filed on 8 Aug 2001, GRANTED, Pat. No. US 6544544 Continuation of Ser.		

No. US 1999-294458, filed on 19 Apr 1999, GRANTED, Pat.
No. US 6506411 Continuation of Ser. No. US 1995-480260,
filed on 7 Jun 1995, ABANDONED Division of Ser. No. US
1995-417160, filed on 3 Apr 1995, ABANDONED
Continuation-in-part of Ser. No. US 1993-94536, filed
on 19 Jul 1993, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	76 Drawing Page(s)	
LINE COUNT:	5042	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an
anti-angiogenic factor, and a polymeric carrier. Representative examples
of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids
and derivatives thereof, and **paclitaxel**. Also provided are
methods for embolizing blood vessels, and eliminating biliary, urethral,
esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 7 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:63391 USPATFULL
TITLE: Coated implantable medical device
INVENTOR(S): Ragheb, Anthony O., West Lafayette, IN, UNITED STATES
Fearnot, Neal E., West Lafayette, IN, UNITED STATES
Voorhees, William D., III, West Lafayette, JAPAN
Kozma, Thomas G., Canton, GA, UNITED STATES
Bates, Brian L., Bloomington, IN, UNITED STATES
Osborne, Thomas A., Bloomington, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004047909	A1	20040311
APPLICATION INFO.:	US 2003-414444	A1	20030414 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2002-223415, filed on 19 Aug 2002, PENDING Continuation-in-part of Ser. No. US 1998-27054, filed on 20 Feb 1998, PENDING Continuation-in-part of Ser. No. US 1996-645646, filed on 16 May 1996, GRANTED, Pat. No. US 6096070 Continuation-in-part of Ser. No. US 1995-484532, filed on 7 Jun 1995, GRANTED, Pat. No. US 5609629		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-38459P	19970220 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	BRINKS HOFER GILSON & LIONE, P.O. BOX 10395, CHICAGO, IL, 60611	
NUMBER OF CLAIMS:	123	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	5 Drawing Page(s)	
LINE COUNT:	2132	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods of making coated implantable medical devices are provided. The
methods include positioning a first layer comprising a bioactive on at

least a portion of a structure, and positioning at least one porous layer over the first layer. The at least one porous layer has a thickness adequate to provide a **controlled release** of the bioactive.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 8 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:38077 USPATFULL

TITLE: Dopamine agonist formulations for enhanced central nervous system delivery

INVENTOR(S): Quay, Steven C., Edmonds, WA, UNITED STATES

PATENT ASSIGNEE(S): Natestch Pharmaceutical Company Inc, Hauppauge, NY (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004028613	A1	20040212
APPLICATION INFO.:	US 2001-891630	A1	20010625 (9)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	TOWNSEND AND TOWNSEND AND CREW, LLP, TWO EMBARCADERO CENTER, EIGHTH FLOOR, SAN FRANCISCO, CA, 94111-3834		
NUMBER OF CLAIMS:	58		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	8045		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Pharmaceutical formulations are described comprising at least one dopamine receptor agonist and one or more mucosal delivery-enhancing agents for enhanced mucosal delivery of the dopamine receptor agonist. In one aspect, the mucosal delivery formulations and methods provide enhanced delivery of the dopamine receptor agonist to the central nervous system (CNS), for example by yielding dopamine receptor agonist concentrations in the cerebral spinal fluid of 5% or greater of the peak dopamine agonist concentrations in the blood plasma following administration to a mammalian subject. Exemplary formulations and methods within the invention utilize apomorphine as the dopamine receptor agonist. Other exemplary methods and formulations focus in intranasal administration of a dopamine receptor agonist. The formulations and methods of the invention are useful for treating a variety of diseases and conditions in mammalian subjects, including Parkinson's disease, male erectile dysfunction, female sexual dysfunction, among others. In alternate aspects, the mucosal delivery formulations and methods of the invention include one, or any combination of, mucosal delivery-enhancing agents selected from (a) aggregation inhibitory agents; (b) charge modifying agents; (c) pH **control** agents; (d) degradative enzyme inhibitors; (e) mucolytic or mucus clearing agents; (f) ciliostatic agents; (g) membrane penetration-enhancing agents; (h) modulatory agents of epithelial junction physiology; (i) vasodilator agents; (j) selective transport-enhancing agents; and (k) stabilizing delivery vehicles, carriers, supports or complex-forming agents. These methods and formulations of the invention provide for significantly enhanced absorption of dopamine receptor agonists into or across a nasal mucosal barrier to a target site of action, for example the CNS.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 9 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2004:24390 USPATFULL

TITLE: Compositions and methods for reducing scar tissue formation

INVENTOR(S): Fischell, Robert E., Dayton, MD, UNITED STATES

PATENT ASSIGNEE(S): Fischell, Tim A., Kalamazoo, MI, UNITED STATES
Fischell, Sarah T., Fair Haven, NJ, UNITED STATES
Waldorf, Clayton MacKenzie, Richland, MI, UNITED STATES
Afmedica, Inc., Kalamazoo, MI (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004018228	A1	20040129
APPLICATION INFO.:	US 2003-431701	A1	20030507 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2003-351207, filed on 24 Jan 2003, PENDING Continuation of Ser. No. US 2001-772693, filed on 31 Jan 2001, GRANTED, Pat. No. US 6534693 Continuation-in-part of Ser. No. US 2000-705999, filed on 6 Nov 2000, ABANDONED		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	Peter G. Carroll, MEDLEN & CARROLL, LLP, Suite 350, 101 Howard Street, San Francisco, CA, 94105		
NUMBER OF CLAIMS:	39		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	13 Drawing Page(s)		
LINE COUNT:	3687		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention describes the application of sirolimus and analogs of sirolimus to treat wound healing and reduce scar tissue formation. Also contemplated are non-sirolimus compounds believed to interact with the mTOR protein that have similar effects. Specifically, various medium are contemplated to create, for example, **microparticles**, foams, gels, sprays and bioadhesives that may be administered during surgical procedures involving either open or closed surgical site. Coating medical devices for long-term implantation is contemplated as one method of use of the above compositions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 10 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2003:289217 USPATFULL
TITLE: ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE
INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA
MACHAN, LINDSAY S., VANCOUVER, CANADA
ARSENAULT, A. LARRY, PARIS, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003203976	A1	20031030
APPLICATION INFO.:	US 1995-486867	A1	19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	82 Drawing Page(s)	
LINE COUNT:	5235	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples

of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 11 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2003:225376 USPATFULL

TITLE: Compositions and methods for treating or preventing inflammatory diseases

INVENTOR(S): Hunter, William L., Vancouver, CANADA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003157187	A1	20030821
APPLICATION INFO.:	US 2002-172737	A1	20020613 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-368871, filed on 4 Aug 1999, PENDING Continuation-in-part of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	107 Drawing Page(s)	
LINE COUNT:	8457	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 12 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2003:206958 USPATFULL

TITLE: Coating medical devices

INVENTOR(S): Pui, David Y.H., Plymouth, MN, UNITED STATES
Chen, Da-Ren, Creve Coeur, MO, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003143315	A1	20030731
APPLICATION INFO.:	US 2002-301473	A1	20021121 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-858865, filed on 16 May 2001, PENDING		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	MUETING, RAASCH & GEBHARDT, P.A., P.O. BOX 581415, MINNEAPOLIS, MN, 55458		
NUMBER OF CLAIMS:	106		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Page(s)		

LINE COUNT: 2887

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and systems for coating at least a portion of a medical device (e.g., a stent structure) include providing a plurality of coating particles (e.g., monodisperse coating particles) in a defined volume. For example, the particles may be provided using one or more nozzle structures, wherein each nozzle structure includes at least one opening terminating at a dispensing end. The plurality of coating particles may be provided in the defined volume by dispensing a plurality of microdroplets having an electrical charge associated therewith from the dispensing ends of the one or more nozzle structures through use of a nonuniform electrical field between the dispensing ends and the medical device. Electrical charge is concentrated on the particle as the microdroplet evaporates. With a plurality of coating particles provided in the defined volume, such particles can be moved towards at least one surface of the medical device to form a coating thereon (e.g., using an electric field and/or a thermophoretic effect).

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 13 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2003:201367 USPATFULL

TITLE: Compositions and methods for the treatment of inflammatory diseases

INVENTOR(S): Jackson, John K., Vancouver, CA, UNITED STATES
Burt, Helen M., Vancouver, CANADA
Dordunoo, Stephen K., Baltimore, MD, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003139353	A1	20030724
APPLICATION INFO.:	US 2002-220190	A1	20021203 (10)
	WO 2001-CA247		20010228
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	BOZICEVIC, FIELD & FRANCIS LLP, 200 MIDDLEFIELD RD, SUITE 200, MENLO PARK, CA, 94025		
NUMBER OF CLAIMS:	15		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	2283		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Topoisomerase inhibitors are useful for the treatment of inflammatory disorders including arthritis, restenosis, surgical adhesions and other diseases. **Controlled release** polymeric formulations to topoisomerase inhibitors are particularly suitable for this use.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 14 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2003:180370 USPATFULL

TITLE: Compositions and methods for improving integrity of compromised body passageways and cavities

INVENTOR(S): Signore, Pierre E., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA

PATENT ASSIGNEE(S): University of British Columbia, Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003124197	A1	20030703
APPLICATION INFO.:	US 2002-323401	A1	20021218 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-511570, filed on 23 Feb 2000, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-121424P	19990223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1939	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for improving the integrity of body passageways following surgery or injury. Representative examples of therapeutic agents include microtubule stabilizing agents, fibrosis inducers, angiogenic factors, growth factors and cytokines and other factors involved in the wound healing or fibrosis cascade.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 15 OF 36 USPATFULL on STN
 ACCESSION NUMBER: 2003:44389 USPATFULL
 TITLE: Polymer compositions containing bioactive agents and methods for their use
 INVENTOR(S): Van Antwerp, William P., Valencia, CA, UNITED STATES
 PATENT ASSIGNEE(S): Medtronic Minimed, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003031699	A1	20030213
	US 6770729	B2	20040803
APPLICATION INFO.:	US 2002-260786	A1	20020930 (10)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	GATES & COOPER LLP, HOWARD HUGHES CENTER, 6701 CENTER DRIVE WEST, SUITE 1050, LOS ANGELES, CA, 90045		
NUMBER OF CLAIMS:	21		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	1 Drawing Page(s)		
LINE COUNT:	1543		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Embodiments of the invention provide polymer coated implantable medical devices having a bioactive material posited in or on at least a portion of the coating layer, wherein the coating layer provides for the **controlled release** of the bioactive material from the coating layer. Preferably, the medical device is an intravascular stent.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 16 OF 36 USPATFULL on STN
 ACCESSION NUMBER: 2003:4168 USPATFULL
 TITLE: Anti-angiogenic compositions and methods of use
 INVENTOR(S): Hunter, William L., Vancouver, CANADA
 Machan, Lindsay S., Vancouver, CANADA
 Arsenault, A. Larry, Paris, CANADA
 PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, BC, CANADA, V6T 1Z4 (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003004209	A1	20030102
APPLICATION INFO.:	US 2002-112921	A1	20020328 (10)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1998-13765, filed on 27 Jan 1998, ABANDONED Continuation of Ser. No. US 1995-478914, filed on 7 Jun 1995, GRANTED, Pat. No. US 5994341 Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	76 Drawing Page(s)	
LINE COUNT:	5230	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 17 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2003:3060 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
Arsenault, A. Larry, Paris, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003003094	A1	20030102
	US 6544544	B2	20030408
APPLICATION INFO.:	US 2001-925220	A1	20010808 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-294458, filed on 19 Apr 1999, PENDING Continuation of Ser. No. US 1995-480260, filed on 7 Jun 1995, ABANDONED Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	75 Drawing Page(s)	
LINE COUNT:	5049	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral,

esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 18 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:332754 USPATFULL
TITLE: Method for treating multiple sclerosis
INVENTOR(S): Hunter, William L., Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6495579	B1	20021217
APPLICATION INFO.:	US 1998-88546		19980601 (9)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63087P	19971024 (60)
	US 1996-32215P	19961202 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Geist, Gary	
ASSISTANT EXAMINER:	Crane, L. E.	
LEGAL REPRESENTATIVE:	Seed Intellectual Property Law Group PLLC	
NUMBER OF CLAIMS:	29	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	167 Drawing Figure(s); 107 Drawing Page(s)	
LINE COUNT:	8213	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 19 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:323211 USPATFULL
TITLE: Compositions and methods for treating or preventing inflammatory diseases
INVENTOR(S): Hunter, William L., Vancouver, CANADA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Vancouver, CANADA
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002183380	A1	20021205
	US 6689803	B2	20040210
APPLICATION INFO.:	US 2002-67467	A1	20020205 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-368463, filed on 4 Aug 1999, ABANDONED Division of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH	

AVE, SUITE 6300, SEATTLE, WA, 98104-7092
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 107 Drawing Page(s)
LINE COUNT: 8178

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis are provided, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 20 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:295216 USPATFULL
TITLE: ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE
INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA
MACHAN, LINDSAY S., VANCOUVER, CANADA
ARSENAULT, A. LARRY, PARIS ON, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002165265	A1	20021107
APPLICATION INFO.:	US 1997-984258	A1	19971203 (8)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-478203, filed on 7 Jun 1995, GRANTED, Pat. No. US 5716981 Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	82 Drawing Page(s)	
LINE COUNT:	5231	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 21 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:294335 USPATFULL
TITLE: ANTI-ANGIOGENIC COMPOSITIONS AND METHODS OF USE
INVENTOR(S): HUNTER, WILLIAM L, BRITISH COLUMBIA, CANADA
MACHAN, LINDSAY S, BRITISH COLUMBIA, CANADA
ARSENAULT, A LARRY, ONTARIO, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164377	A1	20021107
	US 6506411	B2	20030114
APPLICATION INFO.:	US 1999-294458	A1	19990419 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1995-480260, filed on 7 Jun		

1995, ABANDONED Division of Ser. No. US 1995-417160,
filed on 3 Apr 1995, ABANDONED Division of Ser. No. US
1993-94536, filed on 19 Jul 1993, ABANDONED

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	61	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	82 Drawing Page(s)	
LINE COUNT:	5243	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 22 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:294332 USPATFULL

TITLE: POLYMERIC SYSTEMS FOR DRUG DELIVERY AND USES THEREOF

INVENTOR(S): JACKSON, JOHN, VANCOUVER, CANADA
ZHANG, XICHEN, CASTRO VALLEY, CA, UNITED STATES
BURT, HELEN, VANCOUVER, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002164374	A1	20021107
APPLICATION INFO.:	US 1998-181582	A1	19981028 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1997-63721P	19971029 (60)
	US 1998-76842P	19980304 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	62	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	28 Drawing Page(s)	
LINE COUNT:	2770	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Biodegradable polymeric implants can provide a safe and efficient means to deliver drugs in the treatment of various diseases. Although a polymeric drug delivery system can be implanted as a solid device within a subject, it is also possible to administer such a system as an injectable liquid which solidifies in vivo. An improved formulation of a polymeric drug delivery system comprises a water insoluble copolymer that is a solid or wax at 37° C., a water soluble polymer that is a liquid at 25° C., and a hydrophobic drug. These drug delivery systems can be administered by injection, and do not require the use of a toxic curing agent or inconvenient temperature manipulations.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 23 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:221067 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA
Arsenault, A. Larry, Paris, CANADA
Burt, Helen M., Vancouver, CANADA
Jackson, John K., Vancouver, CANADA
Dordunoo, Stephen K., Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002119202	A1	20020829
APPLICATION INFO.:	US 2001-927882	A1	20010809 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-294458, filed on 19 Apr 1999, PENDING Continuation of Ser. No. US 1995-480260, filed on 7 Jun 1995, ABANDONED Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, ABANDONED Division of Ser. No. US 1993-94536, filed on 19 Jul 1993, ABANDONED		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	75 Drawing Page(s)	
LINE COUNT:	5037	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 24 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:99503 USPATFULL
TITLE: Compositions and methods for treating or preventing diseases of body passageways
INVENTOR(S): Hunter, William L., Vancouver, CANADA
Machan, Lindsay S., Vancouver, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002052404	A1	20020502
	US 6759431	B2	20040706
APPLICATION INFO.:	US 2001-933652	A1	20010820 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1996-653207, filed on 24 May 1996, UNKNOWN		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092		
NUMBER OF CLAIMS:	14		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	94 Drawing Page(s)		
LINE COUNT:	4786		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for treating or preventing diseases associated with body passageways, comprising the step of delivering to an external portion of the body passageway a therapeutic agent. Representative examples of therapeutic agents include anti-angiogenic factors, anti-proliferative agents, anti-inflammatory agents, and antibiotics.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 25 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:67266 USPATFULL
TITLE: COMPOSITIONS AND METHODS OF **PACLITAXEL** FOR
PREVENTING PSORIASIS
INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002037919	A1	20020328
	US 6515016	B2	20030204
APPLICATION INFO.:	US 1997-980549	A1	19971201 (8)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	34	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	107 Drawing Page(s)	
LINE COUNT:	6325	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides methods for treating or preventing inflammatory diseases such as psoriasis or multiple sclerosis, comprising the step of delivering to the site of inflammation an anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 26 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2002:55250 USPATFULL
TITLE: Coated implantable medical device
INVENTOR(S): Ragheb, Anthony O., West Lafayette, IN, UNITED STATES
Bates, Brian L., Bloomington, IN, UNITED STATES
Fearnot, Neal E., West Lafayette, IN, UNITED STATES
Kozma, Thomas G., Lafayette, IN, UNITED STATES
Voorhees, William D., III, West Lafayette, IN, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002032414	A1	20020314
	US 6730064	B2	20040504
APPLICATION INFO.:	US 2001-850691	A1	20010507 (9)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1999-378541, filed on 20 Aug 1999, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97231P	19980820 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	

LEGAL REPRESENTATIVE: Anton P. Ness, Patent Attorney, P.O. Box 2269,
Bloomington, IN, 47402-2269

NUMBER OF CLAIMS: 22

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 5 Drawing Page(s)

LINE COUNT: 1610

AB A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the **controlled release** of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer includes a polymer and provides for the **controlled release** of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a **controlled release** of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.

L9 ANSWER 27 OF 36 USPTAFULL on STN

ACCESSION NUMBER: 2002:43866 USPTAFULL

TITLE: Delivery systems for periadventitial delivery for treatment of restenosis and anastomotic **intimal hyperplasia**

INVENTOR(S): Helmus, Michael N., Worcester, MA, UNITED STATES
Cunanan, Crystal M., Mission Viejo, CA, UNITED STATES
Tremble, Patrice, Santa Rosa, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002026236	A1	20020228
	US 6730313	B2	20040504
APPLICATION INFO.:	US 2001-771480	A1	20010125 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-178087P	20000125 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Debra D. Condino, Esq., Edwards Lifesciences Corp., c/o Edwards Lifesciences LLC, One Edwards Way, Irvine, CA, 92614	
NUMBER OF CLAIMS:	66	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2055	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention provides methods for treating injuries to one or more internal structures of a subject by administering a drug delivery vehicle to an external surface of the injured structure. The drug delivery vehicle substantially **adheres** to the site of administration and provides for the **release** of a bioactive agent that reduces or prevents further injury to the internal structure by disease processes, such as hyperplasia.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 28 OF 36 USPTAFULL on STN

ACCESSION NUMBER: 2002:37339 USPTAFULL

TITLE: Composition and methods for improving integrity of
compromised body passageways and cavities
INVENTOR(S): Signore, Pierre E, Vancouver British Columbia, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002022055	A1	20020221
APPLICATION INFO.:	US 2000-511570	A1	20000223 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-121424P	19990223 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	40	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1938	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions and methods for improving
the integrity of body passageways following surgery or injury.
Representative examples of therapeutic agents include microtubule
stabilizing agents, fibrosis inducers, angiogenic factors, growth
factors and cytokines and other factors involved in the wound healing or
fibrosis cascade.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 29 OF 36 USPATFULL on STN
ACCESSION NUMBER: 2002:22462 USPATFULL
TITLE: COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING
INFLAMMATORY DISEASES
INVENTOR(S): HUNTER, WILLIAM L., VANCOUVER, CANADA

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002013298	A1	20020131
APPLICATION INFO.:	US 1999-368463	A1	19990804 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1998-88546, filed on 1 Jun 1998, PENDING Continuation-in-part of Ser. No. US 1997-980549, filed on 1 Dec 1997, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1996-32215P	19961202 (60)
	US 1997-63087P	19971024 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	45	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	110 Drawing Page(s)	
LINE COUNT:	8318	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions for treating or preventing inflammatory
diseases such as psoriasis or multiple sclerosis are provided,
comprising the step of delivering to the site of inflammation an
anti-microtubule agent, or analogue or derivative thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 30 OF 36 USPATFULL on STN

ACCESSION NUMBER: 2001:172872 USPATFULL
TITLE: Coated implantable medical device
INVENTOR(S): Ragheb, Anthony O., West Lafayette, IN, United States
Bates, Brian L., Bloomington, IN, United States
Fearnot, Neal E., West Lafayette, IN, United States
Kozma, Thomas G., Lafayette, IN, United States
Voorhees, III, William D., West Lafayette, IN, United States
PATENT ASSIGNEE(S): Cook Incorporated, Bloomington, IN, United States (U.S. corporation)
MED Institute Inc., West Lafayette, IN, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6299604	B1	20011009
APPLICATION INFO.:	US 1999-378541		19990820 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-97231P	19980820 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Seidel, Richard K.	
ASSISTANT EXAMINER:	Sirmons, Kevin C.	
LEGAL REPRESENTATIVE:	Ness, Anton P., Godlewski, Richard J.	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1633	

AB A coated implantable medical device 10 includes a structure 12 adapted for introduction into the vascular system, esophagus, trachea, colon, biliary tract, or urinary tract; at least one coating layer 16 posited on one surface of the structure; and at least one layer 18 of a bioactive material posited on at least a portion of the coating layer 16, wherein the coating layer 16 provides for the **controlled release** of the bioactive material from the coating layer. In addition, at least one porous layer 20 can be posited over the bioactive material layer 18, wherein the porous layer is includes a polymer and provides for the **controlled release** of the bioactive material therethrough. Preferably, the structure 12 is a coronary stent. The porous layer 20 includes a polymer applied preferably by vapor or plasma deposition and provides for a **controlled release** of the bioactive material. It is particularly preferred that the polymer is a polyamide, parylene or a parylene derivative, which is deposited without solvents, heat or catalysts, and merely by condensation of a monomer vapor.

L9 ANSWER 31 OF 36 USPATFULL on STN

ACCESSION NUMBER: 1999:155724 USPATFULL
TITLE: Anti-angiogenic Compositions and methods for the treatment of arthritis
INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PATENT ASSIGNEE(S): Angiogenesis Technologies, Inc., Vancouver, Canada (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5994341		19991130
APPLICATION INFO.:	US 1995-478914		19950607 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Seed & Berry LLP	
NUMBER OF CLAIMS:	8	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	129 Drawing Figure(s); 75 Drawing Page(s)	
LINE COUNT:	5044	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 32 OF 36 USPATFULL on STN

ACCESSION NUMBER: 1999:37140 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals Inc., Vancouver, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5886026		19990323
APPLICATION INFO.:	US 1995-472413		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Seed and Berry LLP	
NUMBER OF CLAIMS:	6	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	130 Drawing Figure(s); 75 Drawing Page(s)	
LINE COUNT:	4997	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 33 OF 36 USPATFULL on STN

ACCESSION NUMBER: 1998:14828 USPATFULL
TITLE: Anti-angiogenic compositions and methods of use
INVENTOR(S): Hunter, William L., Vancouver, Canada
Machan, Lindsay S., Vancouver, Canada
Arsenault, A. Larry, Paris, Canada
PATENT ASSIGNEE(S): Angiogenesis Technologies, Inc., Vancouver, Canada
(non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5716981		19980210
APPLICATION INFO.:	US 1995-478203		19950607 (8)
RELATED APPLN. INFO.:	Division of Ser. No. US 1995-417160, filed on 3 Apr 1995, now abandoned which is a continuation-in-part of Ser. No. US 1993-94536, filed on 19 Jul 1993, now abandoned		

	NUMBER	DATE
PRIORITY INFORMATION:	WO 1994-CA373	19940719
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Kumar, Shailendra	
LEGAL REPRESENTATIVE:	Seed and Berry LLP	
NUMBER OF CLAIMS:	18	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	130 Drawing Figure(s); 75 Drawing Page(s)	
LINE COUNT:	5084	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and **paclitaxel**. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L9 ANSWER 34 OF 36 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1092433 EUROPATFULL EW 200116 FS OS
TITLE: Compositions and methods for treating or preventing inflammatory diseases.
Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.
Compositions and methods for treating or preventing inflammatory diseases.
INVENTOR(S): Hunter, William L., 135 Alexander Street, Vancouver, B.C. V6A 1B8, CA
PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive, Vancouver, British Columbia V6T 1Z4, CA
PATENT ASSIGNEE NO: 1910123
AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT
Franz-Joseph-Strasse 38, 80801 Muenchen, DE
AGENT NUMBER: 61531
OTHER SOURCE: BEPA2001029 EP 1092433 A2 0184
SOURCE: Wila-EPZ-2001-H16-T1b
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R

GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPA2 EUROPÄISCHE PATENTANMELDUNG
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1092433	A2 20010418
'OFFENLEGUNGS' DATE:		20010418
APPLICATION INFO.:	EP 2000-123534	19971202
PRIORITY APPLN. INFO.:	US 1996-32215	19961202
	US 1997-63087	19971024
RELATED DOC. INFO.:	EP 941089	DIV

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 1092433 EUROPATFULL EW 200332 FS PS
TITLE: USE OF ANTI-MICROTUBULE AGENTS FOR TREATING INFLAMMATORY
RESPIRATORY DISEASES OF THE RESPIRATORY TRACT.
VERWENDUNG VON ANTI-MIKROTUBULI MITTELN ZUR BEHANDLUNG
VON ENTZUENDLICHEN ERKRANKUNGEN DER ATEMWEGE.
UTILISATION DES AGENTS ANTI-MICROTUBULES POUR TRAITER
DES MALADIES INFLAMMATOIRES DES VOIES RESPIRATOIRES.
INVENTOR(S): Hunter, William L., 135 Alexander Street, Vancouver,
B.C. V6A 1B8, CA
PATENT ASSIGNEE(S): Angiotech International GmbH, Bundesplatz 1, 6304 Zug,
CH
PATENT ASSIGNEE NO: 4399820
AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT
Pettenkoferstrasse 20-22, 80336 Muenchen, DE
AGENT NUMBER: 61531
OTHER SOURCE: MEPB2003042 EP 1092433 B1 0154
SOURCE: Wila-EPS-2003-H32-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPÄISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND DATE
	EP 1092433	B1 20030806
'OFFENLEGUNGS' DATE:		20010418
APPLICATION INFO.:	EP 2000-123534	19971202
PRIORITY APPLN. INFO.:	US 1996-32215	19961202
	US 1997-63087	19971024
RELATED DOC. INFO.:	EP 941089	DIV
REFERENCE PAT. INFO.:	EP 38567 A	EP 262681 A
	EP 288794 A	EP 717041 A
	WO 94-12158 A	WO 95-03795 A
	WO 95-35095 A	US 5443458 A
	US 5565439 A	
REF. NON-PATENT-LIT.:	DATABASE WPI Week 8619 Derwent Publications Ltd., London, GB; AN 86-123250 XP002062018 & JP61063613 A (MITSUI TOATSU CHEM. INC.), 1 April 1986 (1986-04-01) YA MIN WANG ET AL.: "Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol" CHEM. PHARM. BULL., vol. 44, no. 10, 1996, pages 1935-1940, XP000633466	

L9 ANSWER 35 OF 36 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1090637 EUROPATFULL EW 200115 FS OS

TITLE: Compositions and methods for treating or preventing inflammatory diseases.
Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.
Compositions and methods for treating or preventing inflammatory diseases.

INVENTOR(S): Hunter, William L., 135 Alexander Street, Vancouver B.C. V6A 1B8, CA

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive, Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT
Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 61531

OTHER SOURCE: BEPA2001027 EP 1090637 A2 0184

SOURCE: Wila-EPZ-2001-H15-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1090637	A2	20010411
		20010411
EP 2000-123537		19971202
US 1996-32215		19961202
US 1997-63087		19971024
EP 941089	DIV	

L9 ANSWER 36 OF 36 EUROPATFULL COPYRIGHT 2004 WILA on STN

PATENT APPLICATION - PATENTANMELDUNG - DEMANDE DE BREVET

ACCESSION NUMBER: 1070502 EUROPATFULL EW 200104 FS OS

TITLE: Compositions and methods for treating or preventing inflammatory diseases.
Zubereitungen und Verfahren zur Behandlung oder Praevention von entzuendlichen Erkrankungen.
Compositions and methods for treating or preventing inflammatory diseases.

INVENTOR(S): The designation of the inventor has not yet been filed

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., 6660 N.W. Marine Drive, Vancouver, British Columbia V6T 1Z4, CA

PATENT ASSIGNEE NO: 1910123

AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT
Franz-Joseph-Strasse 38, 80801 Muenchen, DE

AGENT NUMBER: 61531

OTHER SOURCE: BEPA2001007 EP 1070502 A2 0186

SOURCE: Wila-EPZ-2001-H04-T1b

DOCUMENT TYPE: Patent

LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch

DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE

PATENT INFO.PUB.TYPE: EPA2 EUROPAEISCHE PATENTANMELDUNG

PATENT INFORMATION:

PATENT NO	KIND	DATE
EP 1070502	A2	20010124
		20010124
EP 2000-123557		19971202
US 1996-32215		19961202
US 1997-63087		19971024

'OFFENLEGUNGS' DATE: 20010124

APPLICATION INFO.: EP 2000-123557 19971202

PRIORITY APPLN. INFO.: US 1996-32215 19961202
US 1997-63087 19971024

RELATED DOC. INFO.: EP 941089 DIV

GRANTED PATENT - ERTEILTES PATENT - BREVET DELIVRE

ACCESSION NUMBER: 1070502 EUROPATFULL EW 200323 FS PS
TITLE: USE OF ANTI-MICROTUBULE AGENTS FOR TREATING INFLAMMATORY
BOWEL DISEASES.
VERWENDUNG VON ANTI-MIKROTUBULI MITTELN ZUR BEHANDLUNG
VON ENTZUENDLICHEN DARMERKRANKUNGEN.
UTILISATION DES AGENTS ANTI-MICROTUBULES POUR TRAITER
DES MALADIES INTESTINALES INFLAMMATOIRES.
INVENTOR(S): Hunter, William L., 135 Alexander Street, Vancouver,
B.C. V6A 1B8, CA
PATENT ASSIGNEE(S): Angiotech International GmbH, Bundesplatz 1, 6304 Zug,
CH
PATENT ASSIGNEE NO: 4399820
AGENT: Gowshall, Jonathan Vallance, FORRESTER & BOEHMERT
Pettenkoferstrasse 20-22, 80336 Muenchen, DE
AGENT NUMBER: 61531
OTHER SOURCE: MEPB2003032 EP 1070502 B1 0154
SOURCE: Wila-EPS-2003-H23-T1
DOCUMENT TYPE: Patent
LANGUAGE: Anmeldung in Englisch; Veroeffentlichung in Englisch
DESIGNATED STATES: R AT; R BE; R CH; R DE; R DK; R ES; R FI; R FR; R GB; R
GR; R IE; R IT; R LI; R LU; R MC; R NL; R PT; R SE
PATENT INFO.PUB.TYPE: EPB1 EUROPAEISCHE PATENTSCHRIFT
PATENT INFORMATION:

	PATENT NO	KIND	DATE
	EP 1070502	B1	20030604
'OFFENLEGUNGS' DATE:			20010124
APPLICATION INFO.:	EP 2000-123557		19971202
PRIORITY APPLN. INFO.:	US 1996-32215		19961202
	US 1997-63087		19971024
RELATED DOC. INFO.:	EP 941089	DIV	
REFERENCE PAT. INFO.:	EP 38567 A	EP 262681	A
	EP 288794 A	EP 717041	A
	WO 94-12158 A	WO 95-03795	A
	WO 95-35095 A	US 5443458	A
	US 5565439 A		
REF. NON-PATENT-LIT.:	DATABASE WPI Week 8619 Derwent Publications Ltd., London, GB; AN 86-123250 XP002062018 & JP61063613 A (MITSUI TOATSU CHEM. INC.), 1 April 1986 (1986-04-01) YA MIN WANG ET AL.: "Preparation and characterization of poly(lactic-co-glycolic acid) microspheres for targeted delivery of a novel anticancer agent, taxol" CHEM. PHARM. BULL., vol. 44, no. 10, 1996, pages 1935-1940, XP000633466		